Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Plesha Scott M.

2. Date of Event Requiring Statement (MM/DD/YYYY) 12/20/2017

3. Issuer Name and Ticker or Trading Symbol

BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]

(Last) (First) (Middle)

C/O BIODELIVERY SCIENCES INTL, INC.,, 4131 PARKLAKE AVE. SUITE 225

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
President /

(Street)

RALEIGH, NC 27612

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	130031	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽¹⁾ ⁽⁴⁾	8/10/2018	Common Stock	109296	$0.00	D
Restricted Stock Units	⁽²⁾ ⁽⁴⁾	3/1/2019	Common Stock	35000	$0.00	D
Restricted Stock Units	⁽³⁾ ⁽⁴⁾	2/6/2020	Common Stock	25000	$0.00	D

Explanation of Responses:
(1)	The Restricted Stock Units (each a "RSU") were issued to Scott M. Plesha (the "Reporting Person") on August 10, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). The RSUs vested as to one-third on, (i) August 10, 2016; and; (ii) August 10, 2017. One-third of the RSUs will vest on August 10, 2018.
(2)	The RSUs were issued to the Reporting Person on February 29, 2016, pursuant to a grant under the Plan. The RSUs vested as to one-third on March 1, 2017. One-third of the RSUs will vest on each of, (i) March 1, 2018; and (ii) March 1, 2019.
(3)	The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Plan. One-third of the RSUs will vest on each of, (i) February 6, 2018; (ii) February 6, 2019; and (iii) February 6, 2020.
(4)	Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Plesha Scott M. C/O BIODELIVERY SCIENCES INTL, INC., 4131 PARKLAKE AVE. SUITE 225 RALEIGH, NC 27612			President

Signatures
/s/ Scott M Plesha		1/2/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.